Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Immunol. 2013 Sep 15;191(6):3297-307. doi: 10.4049/jimmunol.1300200. Epub 2013 Aug 16.
Granulibacter bethesdensis is a Gram-negative pathogen in patients with chronic granulomatous disease (CGD), a deficiency in the phagocyte NADPH oxidase. Repeated isolation of genetically identical strains from the same patient over years, and prolonged waxing and waning seropositivity in some subjects, raises the possibility of long-term persistence. G. bethesdensis resists killing by serum, CGD polymorphonuclear leukocytes (PMN), and antimicrobial peptides, indicating resistance to nonoxidative killing mechanisms. Although G. bethesdensis extends the survival of PMN, persistent intracellular bacterial survival might rely on longer-lived macrophages and their precursor monocytes. Therefore, we examined phagocytic killing by primary human monocytes and monocyte-derived macrophages (MDM). Cells from both normal and CGD subjects internalized G. bethesdensis similarly. G. bethesdensis stimulated superoxide production in normal monocytes, but to a lesser degree than in normal PMN. Normal but not CGD monocytes and MDM killed G. bethesdensis and required in vitro treatment with IFN-γ to maintain this killing effect. Although in vitro IFN-γ did not enhance G. bethesdensis killing in CGD monocytes, it restricted growth in proportion to CGD PMN residual superoxide production, providing a potential method to identify patients responsive to IFN-γ therapy. In IFN-γ-treated CGD MDM, G. bethesdensis persisted for the duration of the study (7 d) without decreasing viability of the host cells. These results indicate that G. bethesdensis is highly resistant to oxygen-independent microbicides of myeloid cells, requires an intact NADPH oxidase for clearance, and can persist long-term in CGD mononuclear phagocytes, most likely relating to the persistence of this microorganism in infected CGD patients.
颗粒杆菌贝氏亚种是吞噬细胞 NADPH 氧化酶缺陷的慢性肉芽肿病(CGD)患者的革兰氏阴性病原体。多年来从同一患者反复分离出遗传上相同的菌株,以及一些患者的血清抗体呈阳性且持续时间长短不一,这提示该病原体可能长期存在。颗粒杆菌贝氏亚种能抵抗血清、CGD 中性粒细胞(PMN)和抗菌肽的杀伤,表明其对非氧化杀伤机制具有抗性。尽管颗粒杆菌贝氏亚种延长了 PMN 的存活时间,但持续的细胞内细菌存活可能依赖于寿命更长的巨噬细胞及其前体细胞单核细胞。因此,我们研究了原代人单核细胞和单核细胞衍生的巨噬细胞(MDM)的吞噬杀伤作用。来自正常和 CGD 患者的细胞对颗粒杆菌贝氏亚种的内化能力相似。颗粒杆菌贝氏亚种能刺激正常单核细胞产生超氧化物,但程度低于正常 PMN。正常单核细胞和 MDM 而非 CGD 单核细胞和 MDM 能杀伤颗粒杆菌贝氏亚种,且需要体外用 IFN-γ处理来维持这种杀伤作用。尽管 IFN-γ在体外不能增强 CGD 单核细胞对颗粒杆菌贝氏亚种的杀伤作用,但它能根据 CGD PMN 剩余超氧化物的产生量来限制其生长,为识别对 IFN-γ治疗有反应的患者提供了一种潜在方法。在 IFN-γ处理的 CGD MDM 中,颗粒杆菌贝氏亚种在研究期间(7 天)持续存在,而宿主细胞的活力没有降低。这些结果表明,颗粒杆菌贝氏亚种对髓细胞的氧非依赖性杀菌剂具有高度抗性,需要完整的 NADPH 氧化酶才能被清除,并且能在 CGD 单核吞噬细胞中长期存在,这很可能与该微生物在感染 CGD 患者中的持续存在有关。